MASI Stock Recent News

Masimo (MASI) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Does Masimo (MASI) have what it takes to be a top stock pick for momentum investors? Let's find out.

Szyman currently serves as the worldwide president of Advanced Patient Monitoring at Becton Dickinson and Co.

Masimo said on Tuesday it has named Becton Dickinson executive Katie Szyman as chief executive officer after a bitter proxy battle with activist hedge fund Politan Capital Management led to the ouster of founder Joe Kiani from the medical device maker's board last year.

IRVINE, Calif.--(BUSINESS WIRE)--Today the Board of Directors (the “Board”) of Masimo (NASDAQ: MASI), a leading global medical innovator, announced that Katie Szyman has been appointed the next Chief Executive Officer (“CEO”) of the Company. Interim CEO Michelle Brennan has been appointed Chairman of Masimo's Board and Lead Independent Director Quentin Koffey has been appointed Vice Chairman. All of these changes are effective as of February 12, 2025. Ms. Szyman is currently worldwide president.

MASI's revenue growth in the fourth quarter is likely to have been boosted by the continued robust adoption of its products.

UPPSALA, SWEDEN / ACCESSWIRE / January 13, 2025 / Senzime (STO:SEZI)(OTCQX:SNZZF) Senzime AB (publ.), a leader in precision-based patient monitoring, today announced that the company has reached a second milestone in its collaboration with Masimo through integration with the Masimo Iris® Gateway.

IRVINE, Calif.--(BUSINESS WIRE)--Masimo Corporation (Nasdaq: MASI), a leading global medical innovator, today announced the appointments of Timothy J. Scannell and Wendy E. Lane to the Company's Board of Directors (the “Board”), effective immediately. Following these appointments, the Board will consist of eight directors. Quentin Koffey, Lead Independent Director of Masimo, stated, “We are pleased to welcome Tim and Wendy as our newest independent directors. Both are high-caliber professionals.

As of Oct. 10, 2024, two stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.

MASI's R&D activities raise optimism about the stock.